C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
c4 therapeutics宣佈合作伙伴貝達藥業在大中華地區爲非小細胞肺癌患者第一次投藥CFT8919口服可利用的EGFR L858R受體異位降解試驗階段1臨床試驗
C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
c4 therapeutics宣佈合作伙伴貝達藥業在大中華地區爲非小細胞肺癌患者第一次投藥CFT8919口服可利用的EGFR L858R受體異位降解試驗階段1臨床試驗
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間